Abstract:Intravenous iron is increasingly used to treat iron‐deficient anaemia (IDA) in pregnancy. A previous network meta‐analysis suggested that intravenous irons have a greater effect on haematological parameters than oral irons; however, the impact on serious pregnancy complications such as postpartum haemorrhage (PPH) or the need for blood transfusion was unclear. Since then, several new randomised controlled trials (RCTs) have been conducted. To evaluate the effect and safety of intravenous versus oral iron preparations for treating IDA in pregnancy. We searched CENTRAL, MEDLINE, Embase, and two trial registries (ClinicalTrials.gov and the WHO ICTRP) for eligible studies. The latest search was performed on 19 March 2024. We included RCTs in pregnant women with confirmed IDA (haemoglobin (Hb) level < 11 g/dL as per World Health Organization (WHO) criteria) comparing intravenous (iron sucrose, ferric carboxymaltose, ferric derisomaltose, ferumoxytol) and oral (ferrous sulfate, ferrous fumarate, ferrous gluconate) iron preparations. Our outcomes were antenatal and postnatal Hb levels, antenatal and postnatal anaemia status, PPH, blood transfusion, maternal satisfaction, maternal well‐being, breastfeeding, maternal mortality, maternal morbidity, and adverse events (AEs). We used the Cochrane RoB 1 tool to assess risk of bias in the included RCTs. We followed standard Cochrane methods. Two review authors independently assessed studies for eligibility and scientific rigour, evaluated the risk of bias of included studies, and extracted data. Where appropriate, we pooled data using a fixed‐effect model in the first instance. We reported dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs) and continuous data as mean differences (MDs) with 95% CIs. We assessed the certainty of the evidence using the GRADE approach. We included 13 RCTs (3939 participants) mainly conducted in India and Africa (8/13). Gestational age at baseline ranged from 13 to 37 weeks, and Hb levels ranged from 5.0 to just below 11.0 g/dL. The most frequently compared preparations were intravenous iron sucrose versus oral ferrous sulfate (5/13). Most RCTs were at low risk of bias, and the certainty of evidence ranged from moderate to very low, mainly due to concerns over attrition bias, imprecision, and inconsistency. Antenatal outcomes Compared with oral iron, intravenous iron likely slightly increases Hb level three to six weeks after treatment start (MD 0.49, 95% CI 0.28 to 0.69; 11 RCTs; 2935 participants; moderate‐certainty evidence ) and likely reduces anaemia status three to six weeks after treatment start (RR 0.81, 95% CI 0.77 to 0.86; 5 RCTs; 2189 participants; moderate‐certainty evidence ). Compared with oral iron, intravenous iron likely slightly increases Hb level around birth (MD 0.55, 95% CI 0.33 to 0.77; 6 RCTs; 1574 participants; moderate‐certainty evidence ) and likely reduces anaemia status around birth (RR 0.85, 95% CI 0.77 to 0.93; 4 RCTs; 1240 participants; moderate‐certainty evidence ). Postpartum outcomes Compared with oral iron, intravenous iron may slightly increase Hb level postpartum (MD 0.54, 95% CI 0.41 to 0.68; 3 RCTs; 1950 participants; low‐certainty evidence ). It may also reduce anaemia status (RR 0.66, 95% CI 0.59 to 0.73; 3 RCTs; 1950 participants; low‐certainty evidence ) and severe anaemia postpartum (RR 0.16, 95% CI 0.03 to 0.84; 2 RCTs; 1581 participants; very low‐certainty evidence ), although the evidence for the latter outcome is very uncertain. Compared with oral iron, intravenous iron may result in little to no difference in PPH (RR 1.44, 95% CI 0.50 to 4.20; 3 RCTs; 2251 participants; low‐certainty evidence ) and likely results in little to no difference in the need for blood transfusion (RR 0.97, 95% CI 0.58 to 1.60; 6 RCTs; 2592 participants; moderate‐certainty evidence ) or rates of breastfeeding (RR 1.04, 95% CI 0.97 to 1.12; 1 RCT; 404 participants; moderate‐certainty evidence ). No trials reported on maternal satisfaction or maternal well‐being. Adverse outcomes Compared with oral iron, intravenous iron may have little to no effect on maternal mortality, but the evidence is very uncertain (RR 0.91, 95% CI 0.13 to 6.39; 4 RCTs; 2152 participants; very low‐certainty evidence ). Compared with oral iron, intravenous iron likely does not increase maternal morbidity: severe infections (RR 1.01, 95% CI 0.47 to 2.18; 1 RCT; 1881 participants; moderate‐certainty evidence ) and prolonged hospital stay (RR 0.86, 95% CI 0.62 to 1.21; 1 RCT; 1764 participants; moderate‐certainty evidence ) and may not increase admissions to the intensive care unit (ICU) (RR 1.99, 95% CI 0.18 to 21.87; 2 RCTs; 2069 participants; low‐certainty evidence ). Compared with oral iron, intravenous iron likely does not increase AEs (RR 1.05 -Abstract Truncated-

Iron Deficiency Anemia in Pregnancy: Novel Approaches for an Old Problem

Iron Deficiency Anaemia in Pregnancy: A Narrative Review from a Clinical Perspective

Iron Deficiency and Iron Deficiency Anemia: Implications and Impact in Pregnancy, Fetal Development, and Early Childhood Parameters

Treatment of anemia using parenteral iron supplements

Anaemia and iron deficiency in pregnancy and adverse perinatal outcomes in Southern India

Overview of iron deficiency and iron deficiency anemia in women and girls of reproductive age

The Critical Role of the Early Evaluation of Iron and Vitamin B12 Deficiency in Pregnancy

Prophylactic Iron Supplementation in Pregnancy: A Controversial Issue

Perinatal Iron Deficiency: Implications for Mothers and Infants

Screening, Treatment, and Monitoring of Iron Deficiency Anemia in Pregnancy and Postpartum

Research Progress on the Clinical Treatment of Iron Deficiency Anemia in Pregnancy by Combining Chinese and Western Medicine

Iron Supplementation during Pregnancy and Infancy: Uncertainties and Implications for Research and Policy

Iron deficiency in pregnant women: effect on offspring neuropsychic development

Is It Time to Alter the Standard of Care for Iron Deficiency/Iron Deficiency Anemia in Reproductive-Age Women?

Impact of maternal iron deficiency anemia on fetal iron status and placental iron transporters in human pregnancy

Iron Supplementation Affects Hematologic Biomarker Concentrations and Pregnancy Outcomes among Iron-Deficient Tanzanian Women

Iron Deficiency in Women's Health: New Insights into Diagnosis and Treatment

A Retrospective Study of Various Iron Preparations Oral Administration in Pregnant Women with Iron Deficiency Anemia

Role of mineral nutrients other than iron in pregnancy: under recognized opportunities to improve maternal/fetal outcomes: a literature review

Prediction of Iron Deficiency Anemia in Third Trimester of Pregnancy Based on Data in the First Trimester: A Prospective Cohort Study in a High-Income Country

Effect and safety of intravenous iron compared to oral iron for treatment of iron deficiency anaemia in pregnancy